A retrospective study was conducted on 21 patients with AML (n = 16) or MDS (n = 5) who received anti-PD-1 (16 patients) or anti-CTLA-4 (5 patients) therapy for disease relapse after allo-HCT. The gene discussed is PDCD1; the disease is acute myeloid leukemia.